BARBARA DALTON

Barbara Dalton is a prominent figure in the life sciences investment landscape, holding the position of Vice President at Pfizer Venture Investments (PVI). In this pivotal role, she is instrumental in driving Pfizer's commitment to fostering innovation outside its internal research and development pipeline. PVI, as the corporate venture arm of Pfizer Inc., is dedicated to investing in early-stage biotechnology, life sciences, and digital health companies that are developing groundbreaking solutions with the potential to transform patient care.

As Vice President, Barbara's responsibilities encompass identifying, evaluating, and executing investments in promising startups. Her investment focus areas are deeply rooted in the life sciences, encompassing novel therapeutics across various disease areas, advanced diagnostics, and cutting-edge digital health technologies. She actively seeks out companies that are pioneering new scientific approaches and possess strong potential for clinical and commercial success, often aligning with Pfizer's strategic therapeutic areas and research interests. This involves rigorous due diligence, strategic partnership development, and active portfolio management to help these nascent companies grow from concept to commercialization.

Barbara Dalton brings a wealth of experience and scientific acumen to her role at PVI. Her career background typically includes significant time spent in pharmaceutical research and development, corporate strategy, or business development within the biotech and pharma sectors. This deep operational understanding of drug discovery, clinical development, and commercialization pathways provides her with a unique perspective when assessing investment opportunities. Her academic credentials likely include advanced degrees in relevant scientific disciplines, further solidifying her expertise in evaluating complex scientific propositions and technological innovations. This blend of scientific rigor and business insight makes her an invaluable asset to both Pfizer and its portfolio companies, guiding them through critical development stages.

While specific individual investments she has led are often part of a broader PVI portfolio strategy, Barbara plays a critical role in shaping the direction and success of numerous early-stage ventures. She is involved in identifying companies that are at the forefront of scientific discovery, from novel gene therapies to next-generation small molecule drugs and innovative medical devices. Her work contributes significantly to PVI's track record of supporting companies that go on to achieve significant milestones, including successful clinical trials, regulatory approvals, and strategic partnerships. Her involvement helps ensure that these promising technologies receive the necessary capital and strategic guidance to advance their missions and ultimately bring new therapies and solutions to patients worldwide, reinforcing Pfizer's commitment to global health innovation.